Jubilant Life Sciences Q3 net profit was up 78% at Rs.212.5 crore, while in the same quarter last fiscal year it was at Rs.119.4 crore.

Revenue increased 41.8% at Rs.2,067.8 crore against Rs.1458.2 crore. Earnings before interest, taxes, depreciation and amortization (EBITDA) hiked 25.6% at Rs.416.8 crore, while (EBITDA) margin was down at 20.2%.

Read EquityPandit’s Technical Analysis of Nifty Pharma